HIMS
Bearish signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Hims & Hers Health, Inc.
- Nom
- Hims & Hers Health, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Care Facilities
- Bourse
- NYSE
- Capitalisation
- $6.4B
- Employés
- 2,442
- PDG
- Andrew Dudum
- Site web
- https://www.hims.com
- Marché
- CABRCOTYELELFEPCHELE
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 16 773 titres (~467 128,05 $ US)
- Insiders
- Autor Deborah M.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$3,957,231
Avg sell (VWAP, 90d window) $28.59 vs last close $29.21 (+2.2%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$3,957,231 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-18
- Liquidity
- Liquid $299,390,863/day · 20d vol
- Last synced
-
2026-10-21 21:10:32
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-14 | Boughton Soleil | Sell · S · 10b5-1 | 3,461 | $29.06 | $100,577 | Form 4 |
| 2026-10-01 | Okupe Oluyemi | Sell · S · 10b5-1 | 2,000 | $29.70 | $59,400 | Form 4 |
| 2026-09-30 | Boughton Soleil | Sell · S · 10b5-1 | 3,461 | $29.17 | $100,957 | Form 4 |
| 2026-09-22 | Okupe Oluyemi | Sell · S · 10b5-1 | 29,277 | $29.95 | $876,846 | Form 4 |
| 2026-09-17 | Okupe Oluyemi | Sell · S · 10b5-1 | 12,313 | $28.82 | $354,861 | Form 4 |
| 2026-09-16 | Boughton Soleil | Sell · S · 10b5-1 | 6,236 | $27.86 | $173,735 | Form 4 |
| 2026-09-15 | Chi Michael | Sell · S · 10b5-1 | 14,027 | $28.39 | $398,227 | Form 4 |
| 2026-09-15 | Elshenawy Mohamed | Sell · S · 10b5-1 | 7,954 | $28.39 | $225,814 | Form 4 |
| 2026-09-02 | Boughton Soleil | Sell · S · 10b5-1 | 3,458 | $28.33 | $97,965 | Form 4 |
| 2026-08-19 | Boughton Soleil | Sell · S · 10b5-1 | 25,111 | $27.55 | $691,808 | Form 4 |
| 2026-08-19 | Okupe Oluyemi | Sell · S · 10b5-1 | 4,938 | $29.99 | $148,111 | Form 4 |
| 2026-08-18 | Autor Deborah M. | Sell · S · 10b5-1 | 16,773 | $27.85 | $467,128 | Form 4 |
| 2026-08-17 | Okupe Oluyemi | Sell · S · 10b5-1 | 9,388 | $27.89 | $261,802 | Form 4 |
| 2026-06-18 | Okupe Oluyemi | Sell · S · 10b5-1 | 55,383 | $35.09 | $1,943,389 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-08-04 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
HIMS presents a deeply unfavorable event-driven profile: active securities class action lawsuits, a 14.73% stock drop, and zero insider buying signal severe near-term headwinds that override its improving profitability…
The first sentence of the analysis written for HIMS on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $2.7M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $2.7M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.90 · operating margin 4.5%
Suggested stop 23.27, nearest stored support minus 0.5 ATR(20.3% under the last close). Reward/risk to the next stored resistance is 0.55. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 What Does Hims & Hers Health, Inc.''s 14.73% Stock Drop Mean for Investors? The Law Offices of Howard G. Suit alleges Hims & Hers Health, Inc. failed to disclose key facts to investors from August 4, 2025 through July 29, 2026; lead plaintiff deadline is November 2, 2026 BENSALEM TOWNSHIP, Pa., Oct. 19, 2026 /PRNewswire/ -- The Law Offices of Howard G.
- 2026-10-19 HIMS DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- 2026-10-19 HIMS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Hims (HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hims between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 19, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (""Hims" or the "Company") (NYSE: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 2026-10-19 Deadline Alert: Hims & Hers Health, Inc. Investors Have Until November 2, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Class action covers investors who bought Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026; complaint alleges the company failed to disclose material adverse facts Class action covers investors who bought Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026; complaint alleges the company failed to disclose material adverse facts
- 2026-10-19 HIMS 2-WEEK DEADLINE ALERT: Hims & Hers Health Faces Securities Fraud Class Action, Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC''s sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct. Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.
- 2026-10-19 Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 22025,and July 29, 2026 (the "Class Period"). Investors who purchased Hims & Hers shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for November 2, 2026.
- 2026-10-19 HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
- 2026-10-19 Kaplan Fox Notifies Hims & Hers Health, Inc. (NYSE: HIMS) Investors of a Securities Class Action Lawsuit – Deadline is November 2, 2026 NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.
- 2026-10-19 Hims & Hers Health: The Lollapalooza Effect Of GLP-1s Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, sticky consumer habits. HIMS benefits from powerful psychological drivers—pain avoidance, reward optimization, envy, and social proof—fueling rapid ARPU growth and long-term retention. I model conservative revenue growth to $3.5B in 2026, scaling to strong operating margins, and derive a fair value of $104 per share (272% upside).
- 2026-10-19 Kaplan Fox Advises Hims & Hers Health, Inc. (NYSE) Investors With Losses to Contact the Firm Ahead of the November 2, 2026 Deadline New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 73.8% | 79.5% | 82.0% | 77.6% | 75.2% | |
| Ebit Margin | 5.3% | 4.9% | -2.5% | -12.5% | -40.8% | |
| Ebitda Margin | 7.6% | 6.0% | -1.4% | -11.1% | -39.3% | |
| Operating Profit Margin | 4.5% | 4.2% | -3.4% | -13.0% | -42.3% | |
| Pretax Profit Margin | 5.3% | 4.9% | -2.5% | -12.5% | -40.8% | |
| Continuous Operations Profit Margin | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | |
| Net Profit Margin | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | |
| Bottom Line Profit Margin | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | |
| Current Ratio | 1.898 | 1.788 | 2.996 | 4.518 | 3.407 | |
| Quick Ratio | 1.612 | 1.497 | 2.742 | 4.068 | 3.236 | |
| Solvency Ratio | 0.113 | 0.620 | -0.144 | -1.066 | -1.205 | |
| Cash Ratio | 0.565 | 0.996 | 1.093 | 0.976 | 0.906 | |
| Price To Earnings Ratio | 56.965 | 41.690 | -80.909 | -20.031 | -11.293 | |
| Price To Earnings Growth Ratio | -33.040 | -0.066 | 1.233 | 0.447 | -0.823 | |
| Forward Price To Earnings Growth Ratio | -33.040 | -0.066 | 1.233 | 0.447 | -0.823 | |
| Price To Earnings Diluted Ratio | 63.667 | 45.623 | -80.909 | -20.031 | -11.293 | |
| Price To Earnings Diluted Growth Ratio | -16.872 | -0.078 | 1.233 | 0.447 | -0.823 | |
| Price To Book Ratio | 13.504 | 10.953 | 5.416 | 4.205 | 3.656 | |
| Price To Sales Ratio | 3.111 | 3.536 | 2.137 | 2.488 | 4.500 | |
| Price To Free Cash Flow Ratio | 98.761 | 26.326 | 39.649 | -38.811 | -31.036 | |
| Price To Operating Cash Flow Ratio | 24.348 | 20.795 | 25.355 | -49.412 | -35.552 | |
| Debt To Assets Ratio | 0.520 | 0.016 | 0.023 | 0.014 | 0.013 | |
| Debt To Equity Ratio | 2.072 | 0.024 | 0.029 | 0.017 | 0.016 | |
| Debt To Capital Ratio | 0.674 | 0.023 | 0.028 | 0.017 | 0.016 | |
| Long Term Debt To Capital Ratio | 0.643 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.983 | 1.484 | 1.282 | 1.175 | 1.257 | |
| Working Capital Turnover Ratio | 8.733 | 8.412 | 5.052 | 2.933 | 1.885 | |
| Operating Cash Flow Ratio | 0.742 | 1.134 | 0.831 | -0.553 | -0.434 | |
| Operating Cash Flow Sales Ratio | 0.128 | 0.170 | 0.084 | -0.050 | -0.127 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.247 | 0.790 | 0.639 | 1.273 | 1.146 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.268 | 22.132 | 7.387 | -4.999 | -6.277 | |
| Capital Expenditure Coverage Ratio | 1.327 | 4.760 | 2.774 | -3.661 | -6.873 | |
| Dividend Paid And Capex Coverage Ratio | 1.327 | 4.760 | 2.774 | -3.661 | -6.873 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 45.937 | 56.444 | -147.350 | -21.799 | -10.843 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 73.8% | ▼-5.6% | ▼-3.8% |
| Ebit Margin | 5.3% | ▲0.4% | ▲14.4% |
| Ebitda Margin | 7.6% | ▲1.6% | ▲15.2% |
| Operating Profit Margin | 4.5% | ▲0.3% | ▲14.5% |
| Pretax Profit Margin | 5.3% | ▲0.4% | ▲14.4% |
| Continuous Operations Profit Margin | 5.5% | ▼-3.1% | ▲13.6% |
| Net Profit Margin | 5.5% | ▼-3.1% | ▲13.6% |
| Bottom Line Profit Margin | 5.5% | ▼-3.1% | ▲13.6% |
| Current Ratio | 1.898 | ▲0.110 | ▼-1.023 |
| Quick Ratio | 1.612 | ▲0.115 | ▼-1.019 |
| Solvency Ratio | 0.113 | ▼-0.507 | ▲0.450 |
| Cash Ratio | 0.565 | ▼-0.431 | ▼-0.342 |
| Price To Earnings Ratio | 56.965 | ▲15.275 | ▲59.681 |
| Price To Earnings Growth Ratio | -33.040 | ▼-32.973 | ▼-26.590 |
| Forward Price To Earnings Growth Ratio | -33.040 | ▼-32.973 | ▼-26.590 |
| Price To Earnings Diluted Ratio | 63.667 | ▲18.044 | ▲64.255 |
| Price To Earnings Diluted Growth Ratio | -16.872 | ▼-16.793 | ▼-13.653 |
| Price To Book Ratio | 13.504 | ▲2.551 | ▲5.957 |
| Price To Sales Ratio | 3.111 | ▼-0.425 | ▼-0.043 |
| Price To Free Cash Flow Ratio | 98.760 | ▲72.434 | ▲79.783 |
| Price To Operating Cash Flow Ratio | 24.348 | ▲3.552 | ▲27.241 |
| Debt To Assets Ratio | 0.520 | ▲0.504 | ▲0.403 |
| Debt To Equity Ratio | 2.072 | ▲2.048 | ▲1.640 |
| Debt To Capital Ratio | 0.674 | ▲0.651 | ▲0.523 |
| Long Term Debt To Capital Ratio | 0.643 | ▲0.643 | ▲0.514 |
| Financial Leverage Ratio | 3.983 | ▲2.499 | ▲2.147 |
| Working Capital Turnover Ratio | 8.733 | ▲0.321 | ▲3.330 |
| Operating Cash Flow Ratio | 0.742 | ▼-0.392 | ▲0.398 |
| Operating Cash Flow Sales Ratio | 0.128 | ▼-0.042 | ▲0.087 |
| Free Cash Flow Operating Cash Flow Ratio | 0.246 | ▼-0.543 | ▼-0.572 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.268 | ▼-21.864 | ▼-3.434 |
| Capital Expenditure Coverage Ratio | 1.327 | ▼-3.433 | ▲1.662 |
| Dividend Paid And Capex Coverage Ratio | 1.327 | ▼-3.433 | ▲1.662 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 45.937 | ▼-10.507 | ▲61.459 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $7.30B | $5.22B | $1.86B | $1.31B | $1.22B | |
| Enterprise value | $8.20B | $5.01B | $1.78B | $1.27B | $1.16B | |
| EV / Sales | 3.49x | 3.40x | 2.04x | 2.41x | 4.26x | |
| EV / Op. cash flow | 27.32x | 19.96x | 24.18x | -47.85x | -33.62x | |
| EV / Free cash flow | 110.82x | 25.27x | 37.80x | -37.58x | -29.35x | |
| EV / EBITDA | 45.94x | 56.44x | -147.35x | -21.80x | -10.84x | |
| Net debt / EBITDA | 5.00x | -2.36x | 7.19x | 0.71x | 0.62x | |
| Current ratio | 1.90x | 1.79x | 3.00x | 4.52x | 3.41x | |
| Income quality | 2.34x | 1.99x | -3.12x | 0.40x | 0.32x | |
| Graham number | $6 | $5 | — | — | — | |
| Graham net-net | -$4 | $0 | $1 | $1 | $1 | |
| Tax burden | 103.6% | 175.8% | 109.2% | 100.0% | 97.2% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $363.2M | $174.5M | $176.6M | $168.7M | $190.7M | |
| Invested capital | $1.29B | $423.6M | $351.8M | $317.5M | $332.6M | |
| Return on assets | 6.0% | 17.8% | -5.3% | -17.9% | -25.6% | |
| Operating ROA | 7.4% | 10.8% | -7.3% | -17.5% | -42.7% | |
| Return on tangible assets | 7.6% | 22.9% | -7.6% | -28.1% | -37.9% | |
| Return on equity | 23.7% | 26.4% | -6.8% | -21.1% | -32.2% | |
| Return on invested capital | 6.0% | 12.7% | -8.3% | -21.5% | -32.6% | |
| Return on capital employed | 6.0% | 12.7% | -8.4% | -21.6% | -33.7% | |
| Earnings yield | 1.8% | 2.4% | -1.3% | -5.0% | -8.8% | |
| Free cash flow yield | 1.0% | 3.8% | 2.5% | -2.6% | -3.2% | |
| Capex / Op. cash flow | 75.3% | 21.0% | 36.1% | -27.3% | -14.6% | |
| Capex / Depreciation | 414.7% | 308.7% | 278.4% | 97.0% | 122.9% | |
| Capex / Sales | 9.6% | 3.6% | 3.0% | 1.4% | 1.8% | |
| SG&A / Sales | 50.8% | 57.3% | 66.1% | 70.4% | 91.8% | |
| R&D / Sales | 6.4% | 5.3% | 5.5% | 5.5% | 8.2% | |
| Stock comp / Sales | 5.8% | 6.3% | 7.6% | 8.1% | 24.7% | |
| Intangibles / Total assets | 22.0% | 22.1% | 29.3% | 36.2% | 32.5% | |
| Days sales outstanding | 5d | 2d | 3d | 2d | 5d | |
| Days payables outstanding | 85d | 110d | 100d | 100d | 106d | |
| Operating cycle | 74d | 79d | 55d | 69d | 78d | |
| Cash conversion cycle | -11d | -31d | -45d | -31d | -28d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years